late-stage clinical biotechnology company

funding

North Texas’ Secretome Therapeutics Raises $30M Series A to Advance Muscular Dystrophy-Related Drug

by | May 28, 2026
The financing from Boston's RA Capital Management will support company operations and the continued development of Secretome’s pipeline of innovative treatments, including STM-01, an nCPC-derived therapy in development for treating Duchenne muscular dystrophy, which has had few therapeutic options.
MORE
Dallas’ Nanoscope Therapeutics Hires Chief Technology, Manufacturing Officer
by | Dec 6, 2024
Ray Kaczmarek—the former CEO of Genezen—is an expert in gene therapy manufacturing with decades of experience leading operations, technology, and commercial supply strategies at pharmaceutical and biotech companies, Nanoscope said.
MORE